Abstract:Background: Homologous recombination deficiency (HRD) inhibits double strand breaks from being repaired in DNA, leading to cancer cells failing to recover themselves and cell death. Previous studies found that HRD-positive ovarian cancer patients had more significant clinical benefits from poly ADP-ribose polymerase inhibitors (PARPi) treatment. For accurate detection of HRD, next-generation sequencing (whole exome, whole genome) was used to identify large-scale genomic aberrations including telomeric allelic imbalance (HRD-TAI score), loss of heterozygosity profiles (HRD-LOH score), and large-scale state transitions (HRD-LST score). So far, many studies (HRDetect, SigMA, CHORD and shallowHRD) have been conducted to accurately determine HRD in a pan-cancer cohort. As the study progressed, it has been revealed that PARPi is effective when applied to patients with HRD in not only ovarian cancer but also breast cancer, prostate cancer, and pancreatic cancer. Purpose: To develop an algorithm that accurately predict HRD score in patients with ovarian cancer, breast cancer, prostate cancer, and pancreatic cancer utilizing a machine learning algorithm. Methods: We used whole-genome sequencing (WGS) data of 710 samples from 309 patients, whole-exome sequencing (WES) data of 4,650 samples from 2,193 patients from the pan-cancer cohort of the TCGA (TCGA-OV, TCGA-BRCA, TCGA-PRAD, and TCGA-PAAD). The HRD-TAI/HRD-LST/HRD-LOH scores were calculated through structural variation analyses. After data cleaning processes, machine-learning models were trained and tested on 228 out of 2,502 samples, and validation was performed on 1,248 out of 2,502 samples from the TCGA dataset. Results: To assess the performance of the machine-learning regressor, the concordance between predictions and annotations was quantified by calculating the R squared (R;^2). As a result of training using machine learning algorithm, we achieved a high R;^2 (0.904) with a RMSE (root mean squared error) score (7.649) for a pan-cancer cohort. Conclusions: Our regressor was robust and accurate when applied to 4 cancer types. Using our systematic pan-cancer analysis, we found novel insights into the mechanisms of HRD across cancer types with potential contribution to clinical practice. Citation Format: Boram Choi, Youn Jin Choi. Next-generation sequencing-based regression algorithm to determine homologous recombination deficiency scores in a pan-cancer cohort [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 2328.

Prediction of homologous recombination deficiency from Oncomine Comprehensive Assay Plus correlating with SOPHiA DDM HRD Solution

Abstract 2328: Next-generation sequencing-based regression algorithm to determine homologous recombination deficiency scores in a pan-cancer cohort

expHRD: an individualized, transcriptome-based prediction model for homologous recombination deficiency assessment in cancer

Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer

Genomic Scar Score: A Robust Model Predicting Homologous Recombination Deficiency Based on Genomic Instability

Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer

Optimized Detection of Homologous Recombination Deficiency Improves the Prediction of Clinical Outcomes in Cancer

IdentifiHR: predicting homologous recombination deficiency in high-grade serous ovarian carcinoma using gene expression

A Benchmark of In-House Homologous Recombination Repair Deficiency Testing Solutions for High-Grade Serous Ovarian Cancer Diagnosis

Evaluation of the Oncomine Comprehensive Assay Plus NGS Panel and the OncoScan CNV Assay for Homologous Recombination Deficiency Detection

Variance of HRD score from primary to recurrent in high-grade serous ovarian cancer.

Identification of biomarkers complementary to homologous recombination deficiency for improving the clinical outcome of ovarian serous cystadenocarcinoma

AcornHRD: A novel tool to identify homologous recombination deficiency events in whole genome sequencing data.

Combination of BRCA deep targeted sequencing and shallow whole genome sequencing to detect homologous recombination deficiency in ovarian cancer

Harmonization of Homologous Recombination Deficiency testing in Ovarian Cancer: results from the MITO16A/MaNGO-OV2 trial

Detecting HRD in whole-genome and whole-exome sequenced breast and ovarian cancers

Prediction of homologous recombination deficiency identifies colorectal tumors sensitive to PARP inhibition

Evaluation of Homologous Recombination Deficiency in Ovarian Cancer

Pan-cancer Analysis of Homologous Recombination Deficiency in Cell Lines

Identification of Biomarkers Complementary to Homologous Recombination Deficiency for Improving the Clinical Outcome of Ovarian Serous Cystadenocarcinoma.

Factors associated with an inconclusive result from commercial homologous recombination deficiency testing in ovarian cancer